# HUYABIO International

Source: https://onco.cc/companies/huyabio/  
OnCo record `huyabio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HUYABIO is a San Diego company that licenses Chinese-discovered medicines for the rest of the world; its lead is tucidinostat, the oral HDAC inhibitor approved in China and Japan for T-cell lymphoma, which it took into a phase 3 trial in melanoma with a checkpoint inhibitor.

## Summary

HUYABIO International, based in San Diego, in-licenses drug candidates from Chinese companies and develops them outside China. Its lead compound tucidinostat (HBI-8000, chidamide), a class I HDAC inhibitor approved in China for peripheral T-cell lymphoma and breast cancer and in Japan for lymphoma, was tested with nivolumab in the phase 3 trial registered on ClinicalTrials.gov under HUYABIO as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: HUYABIO International, LLC.; HUYA Bioscience International; HUYABIO
- Tags: ctgov-sponsor
- HQ: San Diego, CA
- Type: biotech
- Website: https://huyabio.com

## Sources

- Official website: https://huyabio.com
- ClinicalTrials.gov: trials led by HUYABIO International, LLC.: https://clinicaltrials.gov/search?lead=HUYABIO%20International%2C%20LLC.
- Wikidata: https://www.wikidata.org/wiki/Q140045552

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- drugs: [Tucidinostat (chidamide)](https://onco.cc/drugs/tucidinostat/)
- companies: [Chipscreen Biosciences](https://onco.cc/companies/chipscreen/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/huyabio.json